ArticleFrontiers in immunology2019
A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Rheumatoid Arthritis: Biomarkers and the Latest Breakthroughs.International journal of molecular sciences · 2025Review
- Emerging concepts and challenges in the development of disease-modifying osteoarthritis drugs - a more refined perspective.Archives of pharmacal research · 2025Review
- BACH1 as a key driver in rheumatoid arthritis fibroblast-like synoviocytes identified through gene network analysis.Life science alliance · 2025Article
- Artificial intelligence in autoimmune diseases: a bibliometric exploration of the past two decades.Frontiers in immunology · 2025Review
- A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease.Nature immunology · 2024Article
- Schizophrenia and Rheumatoid Arthritis Genetic Scenery: Potential Non-HLA Genes Involved in Both Diseases Relationship.The Yale journal of biology and medicine · 2024Article
- A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry.Rheumatology and therapy · 2024Article
- Gene Network Analyses Identify Co-regulated Transcription Factors and BACH1 as a Key Driver in Rheumatoid Arthritis Fibroblast-like Synoviocytes.bioRxiv : the preprint server for biology · 2024Article
- Cell-specific gene networks and drivers in rheumatoid arthritis synovial tissues.Frontiers in immunology · 2024Article
- Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy.Rheumatology (Oxford, England) · 2022Article
- Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search.Rheumatology (Oxford, England) · 2022Review
- -Omic Approaches and Treatment Response in Rheumatoid Arthritis.Pharmaceutics · 2022Review
- ATRPred: A machine learning based tool for clinical decision making of anti-TNF treatment in rheumatoid arthritis patients.PLoS computational biology · 2022Article
- Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.International journal of molecular sciences · 2022Review
- A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.PloS one · 2022Article
- Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy.Annals of the rheumatic diseases · 2022Article
- Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis.International journal of molecular sciences · 2021Review
- Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- Toward Overcoming Treatment Failure in Rheumatoid Arthritis.Frontiers in immunology · 2021Review
- Rheumatology in the era of precision medicine: synovial tissue molecular patterns and treatment response in rheumatoid arthritis.Current opinion in rheumatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 13 institutions in 1 country.
Adrià AteridoRheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
Juan D CañeteRheumatology Department, Hospital Clínic de Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Jesús TorneroRheumatology Department, Hospital Universitario De Guadalajara, Guadalajara, Spain.
Francisco BlancoRheumatology Department, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain.
Benjamín Fernández-GutierrezRheumatology Department, Hospital Clínico San Carlos, Madrid, Spain.
Carolina PérezRheumatology Department, Parc de Salut Mar, Barcelona, Spain.
Mercedes Alperi-LópezRheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Alex OlivèRheumatology Department, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Héctor CorominasRheumatology Department, Hospital Moisès Broggi, Barcelona, Spain.
Víctor Martínez-TaboadaRheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Isidoro GonzálezRheumatology Department, Hospital Universitario La Princesa, IIS La Princesa, Madrid, Spain.
Antonio Fernández-NebroUGC Reumatología, Instituto Investigación Biomédica Málaga, Hospital Regional Universitario, Universidad de Málaga, Málaga, Spain.
Alba ErraRheumatology Department, Hospital Sant Rafael, Barcelona, Spain.
María López-LasantaRheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
Mireia López CorbetoRheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
Núria PalauRheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
Sara MarsalRheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
Antonio JuliàRheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
Vall d'Hebron Institut de Recerca · ESComplexo Hospitalario Universitario A Coruña · ESHospital Clínic de Barcelona · ESHospital Clínico San Carlos · ESHospital de Sant Joan Despí Moisès Broggi · ESHospital Universitari Germans Trias i Pujol · ESHospital Universitario Central de Asturias · ESHospital Universitario de Guadalajara · ESHospital Universitario de La Princesa · ESHospital Universitario San Rafael · ESMarqués de Valdecilla University Hospital · ESParc de Salut · ESUniversidad de Málaga · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene Regulatory NetworksTranscriptomeAdalimumabAntirheumatic AgentsArthritis, RheumatoidBiopsyCohort StudiesFemaleGenome-Wide Association StudyHumansInfliximabMalePolymorphism, Single NucleotideSynovial MembraneTreatment OutcomeTumor Necrosis Factor-alphaAdalimumabAntirheumatic AgentsInfliximabTNF protein, humanTumor Necrosis Factor-alphaanti-TNF therapygenomicsmulti-omics association analysisrheumatoid arthritistranscriptomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.